Skip to main content

Novel NIH initiative enables testing of existing compound as Alzheimer's treatment

The National Institutes of Health has awarded $12.7 million to match nine academic research groups with a selection of pharmaceutical industry compounds to explore new treatments for patients. The treatments, in eight disease areas, include Alzheimer's disease. The project, part of the collaborative pilot initiative called Discovering New Therapeutic Uses for Existing Molecules, will explore whether an investigational drug that blocks Fyn kinase, a type of protein, safely stops Alzheimer’s disease progression in humans.